Japanese Encephalitis Vaccine (JEV)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support is seeking proposals for a Japanese Encephalitis Virus Vaccine (JEV), specifically a purified, inactivated, single-dose prefilled syringe (NSN: 6505-01-607-7018). This presolicitation indicates an upcoming Firm-Fixed Price, Indefinite Delivery, Indefinite Quantity (IDIQ) contract. The successful contractor must have FDA approval to sell JEV. All responsible sources may submit a proposal. The solicitation, SPE2DP-26-R-0001, is expected to be posted on DIBBS.
Scope of Work
This opportunity is for the supply of Japanese Encephalitis Virus Vaccine (JEV), purified, inactivated, and provided in a single-dose prefilled syringe. The vaccine must adhere to the detailed "Salient Characteristics" outlined in MPID Number 5, dated July 23, 2024. Key specifications include:
- FDA-approved for active immunization for persons 2 months of age and up.
- Vero Cell culture derived, sterile suspension, Thimerosal/Preservative-free, and Latex-free.
- Packaged as a sterile 0.5 mL suspension in a pre-filled syringe, with specific dosages for different age groups.
- Minimum 24-month expiration period, with at least 21 months remaining at the time of delivery.
- Requires constant refrigerated shipping and storage (2°-8°C).
- All markings must comply with Medical Marking Standard No. 1D.
Contract Details
- Type: Firm-Fixed Price, Indefinite Delivery, Indefinite Quantity (IDIQ)
- Term: Eighteen (18) month base term
- Quantities: Minimum 277,760 each (EA), Estimated 277,760 each, Maximum 394,240 each
- Delivery: FOB Destination to DLA Distribution Susquehanna, New Cumberland, PA (DODAAC: SV3100)
- Production Lead Time: 120 days after issuance of a delivery order.
- Set-Aside: None specified; open to all responsible sources.
- Authority: The acquisition is planned under 10 U.S.C. § 3204(a)(1), implemented by FAR 6.302-1, indicating a potential sole-source or limited competition, though proposals from all responsible sources will be considered.
Key Requirements for Bidders
Offerors must ensure their proposed JEV product meets all technical specifications detailed in MPID Number 5 and possess FDA approval to sell JEV prior to the solicitation's closing date. Compliance with Medical Marking Standard No. 1D for all shipments is mandatory.
Submission & Contact
The solicitation, SPE2DP-26-R-0001, will be posted on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. Interested parties should register on DIBBS to receive notifications.
- Response Date: May 29, 2026, 03:59 AM UTC
- Point of Contact: Jessica De La Hoz, Contracting Officer, Jessica.DeLaHoz@dla.mil, 445-737-3623. Alec Deichman, Contracting Specialist, Alec.Deichman@dla.mil, 445-737-5743.